Advanced local jejunal carcinoma treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a case report and review of the literature
Open Access
- 20 July 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5377-5381
Abstract
Introduction: Jejunal carcinoma, a rare subset of small bowel adenocarcinomas, is characterized by its aggressive nature and nonspecific clinical presentation. The prognosis becomes particularly poor when peritoneal carcinomatosis is present. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a treatment performed with curative intent for select patients with gastrointestinal cancers, particularly those with limited peritoneal metastases. Case description: A 51-year-old female presented with progressive symptoms of small bowel obstruction and gastrointestinal bleeding, diagnosed as jejunal adenocarcinoma with limited peritoneal carcinomatosis. She underwent CRS combined with HIPEC. Postoperative recovery was uneventful, with imaging studies and pathological analysis confirming complete tumor resection. Discussion and conclusion: HIPEC and CRS have shown potential in managing peritoneal carcinomatosis. However, their efficacy in rare cancers, such as jejunal carcinoma, remains underexplored. Studies show encouraging outcomes for small bowel adenocarcinoma treated with CRS and HIPEC, emphasizing patient selection and multidisciplinary management.Keywords
This publication has 12 references indexed in Scilit:
- Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic reviewPleura and Peritoneum, 2022
- Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trialsEuropean Journal of Surgical Oncology, 2021
- The importance of primary tumor origin in gastrointestinal malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapyWorld Journal of Surgical Oncology, 2020
- Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score AnalysisJournal of Clinical Oncology, 2019
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)Annals of Surgical Oncology, 2019
- Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi ArabiaGastroenterology Research and Practice, 2016
- Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosisWorld Journal of Surgical Oncology, 2016
- Chemotherapy for small-bowel Adenocarcinoma at a single institutionSurgery Today, 2009
- Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) Regimen as an Adjuvant Chemotherapy in the Treatment of Advanced Jejunal Adenocarcinoma: A Report of 2 CasesMedical Principles and Practice, 2008
- Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinomaJournal of Surgical Oncology, 2005